NEW YORK--(BUSINESS WIRE)--
Bragar Eagel & Squire, P.C. is investigating potential claims against Solid Biosciences Inc. (NASDAQ:SLDB). Our investigation concerns whether Solid Biosciences has violated the federal securities laws and/or engaged in other unlawful business practices.
On March 14, 2018, the Company announced it received notification from the U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.
Following this news, shares of Solid Biosciences fell $16.99 per share, or over 64%, to close at $9.32 on March 15, 2018. Since the Company held its IPO on January 26, 2018, its stock price has fallen $6.83 per share, or over 42.5%, to close at $9.17 per share on March 19, 2018.
If you purchased or otherwise acquired Solid Biosciences shares and suffered a loss, continue to hold shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Solid Biosciences Inc., please go to http://www.bespc.com/SLDB. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180319006300/en/
